{"id":52127,"date":"2024-08-05T19:38:35","date_gmt":"2024-08-05T17:38:35","guid":{"rendered":"https:\/\/www.fyb.de\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/"},"modified":"2024-08-05T19:39:02","modified_gmt":"2024-08-05T17:39:02","slug":"biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/","title":{"rendered":"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI"},"content":{"rendered":"

Munich \u2014 Biomat\u00adter, a company in the field of synthe\u00adtic biology, closes a seed finan\u00adcing round of 6.5 million euros.
\nUVC Part\u00adners and Inven\u00adture VC lead the round.
\nExis\u00adting inves\u00adtors Prac\u00adtica Capi\u00adtal and Meta\u00adpla\u00adnet, as well as busi\u00adness angels and indus\u00adtry experts, are also participating.
\nThe start-up plans to use the fresh capi\u00adtal to further expand the plat\u00adform and create funda\u00admen\u00adtally new enzymes.
\nEnzy\u00admes play a key role in various indus\u00adtrial appli\u00adca\u00adti\u00adons, such as in diagno\u00adstics, for exam\u00adple with DNA poly\u00adme\u00adra\u00adses, in gene therapy, for exam\u00adple with CRISPR, in biofuels, for exam\u00adple with cellu\u00adla\u00adses, or in agri\u00adcul\u00adture, for exam\u00adple with phytases.
\nEvery new appli\u00adca\u00adtion requi\u00adres a new enzyme.
\nThe design of new enzy\u00admes is curr\u00adently still leng\u00adthy \u2014 the process can take months or years -, expen\u00adsive and based on trial-and-error scree\u00adning around small impro\u00adve\u00adments to natu\u00adrally occur\u00adring enzymes.
\nBiomat\u00adter\u2019s tech\u00adno\u00adlogy makes it possi\u00adble to over\u00adcome these chal\u00adlenges with gene\u00adra\u00adtive AI (arti\u00adfi\u00adcial intelligence).
\n\u201cEnzy\u00admes will play a promi\u00adnent role in the future of the bioe\u00adco\u00adnomy \u2014 they are the criti\u00adcal element that will ulti\u00adm\u00adately allow us to create new mole\u00adcu\u00adles, cells and orga\u00adnisms for the world. The enzy\u00admes we have successfully deve\u00adlo\u00adped for our global part\u00adners to date demons\u00adtrate our ability to go far beyond the simple opti\u00admiza\u00adtion of known enzy\u00admes. At Biomat\u00adter, we believe that the unli\u00admi\u00adted capa\u00adcity to design funda\u00admen\u00adtally new enzy\u00admes will help shape a better future for all,\u201d says Laury\u00adnas Karpus, co-foun\u00adder and CEO of Biomatter.
\nInno\u00adva\u00adtive tech\u00adno\u00adlogy for a sustainable future<\/strong> Back in 2019, the Biomat\u00adter team published a key study show\u00ading that their gene\u00adra\u00adtive AI tool can under\u00adstand the intri\u00adca\u00adcies of large amounts of enzyme data and use the infor\u00adma\u00adtion to design enti\u00adrely new enzymes.
\nThis was a signi\u00adfi\u00adcant breakth\u00adrough, demons\u00adt\u00adra\u00adting for the first time the ability to create fully func\u00adtional enzy\u00admes with gene\u00adra\u00adtive AI.
\nThe Intel\u00adli\u00adgent Archi\u00adtec\u00adture\u2122 plat\u00adform is the result of these years of research.
\nEnzy\u00admes can be rede\u00adsi\u00adgned as if on a drawing board: First, the ideal proper\u00adties of the enzyme are descri\u00adbed, carefully conside\u00adring the end application.
\nThe enzy\u00admes are then desi\u00adgned from scratch or exis\u00adting natu\u00adral protein scaf\u00adfolds are redesigned.
\nThis enables deve\u00adlo\u00adpers of new prote\u00adins to build precis\u00adely fitting mole\u00adcu\u00adles from the very first atoms.
\nThis inno\u00adva\u00adtion has been made possi\u00adble by the deve\u00adlo\u00adp\u00adment of new gene\u00adra\u00adtive AI and physi\u00adcal models that are constantly impro\u00adving at a rapid pace with expe\u00adri\u00admen\u00adtal vali\u00adda\u00adtion in labo\u00adra\u00adto\u00adries to create unique enzy\u00admes. \u201cAI-powered protein design is curr\u00adently one of the most exci\u00adting and dyna\u00admic areas for venture capi\u00adtal. Biomat\u00adter\u2019s inno\u00adva\u00adtive approach to desig\u00adning funda\u00admen\u00adtally new enzy\u00admes allows them to break the boun\u00adda\u00adries of natu\u00adral enzy\u00admes, leading to breakth\u00adroughs in biotech\u00adno\u00adlogy. We are deeply impres\u00adsed by the strength of the team and are convin\u00adced that Biomat\u00adter is a pioneer in the field of AI-based protein design,\u201d says Dr. Oliver Schoppe, Prin\u00adci\u00adpal at UVC Part\u00adners. Appli\u00adca\u00adtion of unique enzy\u00admes in various indus\u00adtries<\/strong> Using the Intel\u00adli\u00adgent Archi\u00adtec\u00adture\u2122 plat\u00adform, Biomat\u00adter crea\u00adtes custo\u00admi\u00adzed enzy\u00admes for various indus\u00adtries, inclu\u00adding chemi\u00adcal biopro\u00adduc\u00adtion, agri\u00adcul\u00adture, food and medicine.
\nCusto\u00admers include compa\u00adnies such as Thermo Fisher Scien\u00adti\u00adfic, BASF and Neogen.
\nKirin, a global leader in nutri\u00adtion and health, achie\u00adved a breakth\u00adrough in infant nutri\u00adtion with Biomat\u00adter\u2019s solu\u00adtion: The colla\u00adbo\u00adra\u00adtion yiel\u00added amazing results in the effi\u00adci\u00adent produc\u00adtion of human milk oligos\u00adac\u00adcha\u00adri\u00addes (HMOs).
\nThe focus here was speci\u00adfi\u00adcally on one of the most important HMOs in human milk (lacto-N-fuco\u00adpen\u00adta\u00adose I; LNFP I for short).
\nHMOs are criti\u00adcal to infant health and provide nume\u00adrous bene\u00adfits such as support\u00ading gut health, streng\u00adthening the immune system and protec\u00adting against infection.
\nThe ability to produce HMOs like LNFP I on an indus\u00adtrial scale means that more infants world\u00adwide can have access to these bene\u00adfits. About Biomat\u00adter <\/strong> Biomat\u00adter is a synthe\u00adtic biology company that crea\u00adtes new enzy\u00admes for medi\u00adcal and indus\u00adtrial applications.
\nThrough part\u00adner\u00adships with global compa\u00adnies (inclu\u00adding Thermo Fisher Scien\u00adti\u00adfic, BASF, Neogen) across multi\u00adple indus\u00adtries, Biomat\u00adter is brin\u00adging new products and tech\u00adno\u00adlo\u00adgies to market enab\u00adled by its unique enzymes.
\nThis funding round marks a signi\u00adfi\u00adcant mile\u00adstone for Biomat\u00adter and posi\u00adti\u00adons the company well for the comple\u00adtion of its next major mile\u00adsto\u00adnes and future growth.
\nMore at www.biomatter.com About UVC Part\u00adners <\/strong> UVC Part\u00adners is a Munich and Berlin based early stage venture capi\u00adtal firm inves\u00adt\u00ading in Euro\u00adpean B2B start-ups in the fields of enter\u00adprise soft\u00adware, indus\u00adtrial tech\u00adno\u00adlo\u00adgies and mobi\u00adlity. The fund gene\u00adrally invests between \u20ac0.5 and \u20ac10 million at the outset and up to \u20ac30 million in total per company. The port\u00adfo\u00adlio compa\u00adnies bene\u00adfit from the exten\u00adsive invest\u00adment and exit expe\u00adri\u00adence of the manage\u00adment team as well as from the close coope\u00adra\u00adtion with Unter\u00adneh\u00admer\u00adTUM, Euro\u00adpe\u2019s leading inno\u00adva\u00adtion and start-up center. With over 400 employees and more than 100 indus\u00adtry part\u00adners, Unter\u00adneh\u00admer\u00adTUM can draw on many years of expe\u00adri\u00adence in buil\u00adding young compa\u00adnies. This colla\u00adbo\u00adra\u00adtion gives UVC Part\u00adners the oppor\u00adtu\u00adnity to provide start\u00adups with unique access to talent, indus\u00adtry clients and other finan\u00adcial part\u00adners. www.uvcpartners.com<\/p>\n","protected":false},"excerpt":{"rendered":"

Munich \u2014 Biomat\u00adter, a company in the field of synthe\u00adtic biology, closes a seed finan\u00adcing round of 6.5 million euros. UVC Part\u00adners and Inven\u00adture VC lead the round. Exis\u00adting inves\u00adtors Prac\u00adtica Capi\u00adtal and Meta\u00adpla\u00adnet, as well as busi\u00adness angels and indus\u00adtry experts, are also parti\u00adci\u00adpa\u00adting. The start-up plans to use the fresh capi\u00adtal to further expand [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":52125,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1369,1373],"tags":[],"class_list":["post-52127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-investors","category-venture-capital-en"],"yoast_head":"\nBiomatter receives \u20ac 6.5 million for the development of novel enzymes via AI - FYB Financial Yearbook<\/title>\n<meta name=\"description\" content=\"Biomatter, a synthetic biology company, closes a EUR 6.5 million seed financing round. UVC Partners and Inventure VC lead the round. Existing investors Practica Capital and Metaplanet, as well as business angels and industry experts, are also participating. The start-up plans to use the capital to further expand the platform and create fundamentally new enzymes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Biomatter, a synthetic biology company, closes a EUR 6.5 million seed financing round. UVC Partners and Inventure VC lead the round. Existing investors Practica Capital and Metaplanet, as well as business angels and industry experts, are also participating. The start-up plans to use the capital to further expand the platform and create fundamentally new enzymes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-05T17:38:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-05T17:39:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1534\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI\",\"datePublished\":\"2024-08-05T17:38:35+00:00\",\"dateModified\":\"2024-08-05T17:39:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/\"},\"wordCount\":818,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Investors\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/\",\"url\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/\",\"name\":\"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg\",\"datePublished\":\"2024-08-05T17:38:35+00:00\",\"dateModified\":\"2024-08-05T17:39:02+00:00\",\"description\":\"Biomatter, a synthetic biology company, closes a EUR 6.5 million seed financing round. UVC Partners and Inventure VC lead the round. Existing investors Practica Capital and Metaplanet, as well as business angels and industry experts, are also participating. The start-up plans to use the capital to further expand the platform and create fundamentally new enzymes.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg\",\"width\":1534,\"height\":1024,\"caption\":\"Das Team von Biomatter (Foto: Biomatter.com)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI - FYB Financial Yearbook","description":"Biomatter, a synthetic biology company, closes a EUR 6.5 million seed financing round. UVC Partners and Inventure VC lead the round. Existing investors Practica Capital and Metaplanet, as well as business angels and industry experts, are also participating. The start-up plans to use the capital to further expand the platform and create fundamentally new enzymes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/","og_locale":"en_US","og_type":"article","og_title":"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI - FYB Financial Yearbook","og_description":"Biomatter, a synthetic biology company, closes a EUR 6.5 million seed financing round. UVC Partners and Inventure VC lead the round. Existing investors Practica Capital and Metaplanet, as well as business angels and industry experts, are also participating. The start-up plans to use the capital to further expand the platform and create fundamentally new enzymes.","og_url":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2024-08-05T17:38:35+00:00","article_modified_time":"2024-08-05T17:39:02+00:00","og_image":[{"width":1534,"height":1024,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI","datePublished":"2024-08-05T17:38:35+00:00","dateModified":"2024-08-05T17:39:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/"},"wordCount":818,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg","articleSection":["General","Featured","News","Investors","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/","url":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/","name":"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg","datePublished":"2024-08-05T17:38:35+00:00","dateModified":"2024-08-05T17:39:02+00:00","description":"Biomatter, a synthetic biology company, closes a EUR 6.5 million seed financing round. UVC Partners and Inventure VC lead the round. Existing investors Practica Capital and Metaplanet, as well as business angels and industry experts, are also participating. The start-up plans to use the capital to further expand the platform and create fundamentally new enzymes.","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/08\/biomatter-team-biomatter.jpg","width":1534,"height":1024,"caption":"Das Team von Biomatter (Foto: Biomatter.com)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/biomatter-receives-e-6-5-million-for-the-development-of-novel-enzymes-via-ai\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Biomatter receives \u20ac 6.5 million for the development of novel enzymes via AI"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/52127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=52127"}],"version-history":[{"count":1,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/52127\/revisions"}],"predecessor-version":[{"id":52128,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/52127\/revisions\/52128"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/52125"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=52127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=52127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=52127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}